Brain Oxygenation and Mitochondrial Metabolism Differ in Alzheimer’s Disease Model - Technology Networks

Mitochondrial serine catabolic pathway (MSCP), also called serine, glycine, and one-carbon metabolism, is essential for cancer cells to produce amino acids, one-carbon units, and reducing equivalents. The pathway is frequently upregulated in tumors: serine hydroxymethyltransferase 2 (SHMT2) and methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) are among the most overexpressed metabolic enzymes in human cancers, and their activity supports cancer cell proliferation, redox balance, and metastasis. Cancer cells rely on MSCP when the electron transport chain (ETC) is impaired, yet no effective therapy selectively targets this pathway. Fat mass and obesity-associated protein (FTO), an m⁶A demethylase, can be inhibited by 2-hydroxyglutarate (2-HG). FTO expression is associated with favorable prognosis and is downregulated in breast cancer, yet there is currently no effective way to reactivate FTO in cancer. Given these challenges, there is a need for in-depth research on therapies that safely reactivate respiration and target MSCP in metastatic breast cancer. Researchers at Stanford University School of Medicine, with collaborators at The Second Hospital of Jilin University and

Kunda Yang1, Lili Sun2, Yu Cheng1, Kunxiang Liang1, Nixi Huang1, Yunshuang Liu1, Yewenqian Zhang1, Chuangye Liu1 & … Lina Peng2 We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.

(Toronto, October 16, 2026) — JMIR Publications this week released three News and Perspectives features on the latest digital health news: stories on how informed consent must be rethought for clinical trials involving AI; Canada’s proposed Safe Social Media Act and the Canadian Medical Association’s support; and a promising new autonomous oxygen titration device for health care. Designing Informed Consent for AI TrialsIn "Informed Consent in the AI Age: Why and How Documentation Must Change", JMIR Correspondent and researcher Hankun Su argues that traditional informed consent frameworks, which tend to assume that risks to patient safety are static and that clinicians will be able to fill in any gaps in understanding, are inadequate for clinical trials that use AI. “Documents must anticipate questions clinicians cannot answer and provide accessible responses within the text itself,” he writes. Su and his colleagues developed an informed consent framework for AI-related clinical trials that mandates transparency and disclosure, uses tiered standards based on risk, and employs dynamic consent mechanisms—one of many possible frameworks.

Gomez's Hamburger System. This artist's impression of the Gomez's Hamburger system shows the stacked layers of gas and dust as they rotate around a young star. ALMA observations reveal a direct view of its vertical structure at millimeter wavelengths, allowing astronomers to map the location of the millimeter-sized dust grains and several different gas-phase molecules, which have arranged themselves into distinct levels. Credit: NSF/AUI/NSF NRAO/P. Vosteen. Astronomers using the Atacama Large Millimeter/submillimeter Array (ALMA) were surprised to discover the earliest phases of giant planet formation between the dense layers of gas and dust in the "Gomez's Hamburger" system, referred to as GoHam.

The ESA's Euclid Space Telescope has discovered its first comet, a result that's not part of its primary mission. The telescope was launched at the beginning of July, 2023, and its mission is to observe about 1.5 billion galaxies out to redshift z=2, which corresponds to seeing around 10 billion years into the past. The goal is to measure the redshift of a massive amount of galaxies, to shed light on the expansion history of the Universe and the force that drives it, dark energy. The space telescope has observed other comets, but this is the first time it's discovered one. The comet was found in multiple images captured between September 16th and 24th, 2026. For a telescope built to take deep images of distant galaxies, discovering a rapidly moving comet in the Milky Way is a surprising bonus.

If successful, bits of dust, soil and rocks from Phobos will arrive on Earth in 2031. “There’s a lot of adrenaline and a lot of excitement and a lot of wow,” said NASA astrophysicist Tom Statler, who’s involved with the project. Japan has an edge going in, with two asteroid sample returns already under its cosmic belt. Phobos is a lumpy, potato-shaped rock just 14 miles (22 kilometers) or so across. Examining pieces of it can explain how Mars’ moons — and possibly moons elsewhere — came to be. Dubbed MMX for Martian Moons Exploration, the $578 million mission features a hefty 5-ton spacecraft that should reach Mars by late next summer. It will sync up with Phobos’ tight orbit around the red planet, before ejecting the French-German rover that’s named Idefix after the white terrier in the Asterix comics. No bigger than a microwave oven, Idefix will plop onto Phobos by itself, bouncing for several minutes before coming to a halt in the moon’s extraordinarily low gravity. The four-wheeled rover is designed to right itself if it lands upside down. All bets are off, though, if it sinks into soft soil or gets wedged between rocks, said the French Space Agency’s Julien Baroukh.